EU Pharma Revision Proposes Changes To Drug Safety Reporting

The proposed revision of the EU medicines legislation would retain the rules on safety monitoring and reporting much as they are at present, albeit with a few significant changes.

Painted hand shows concept hologram Regulation on his hand. Drawn man in business suit with future technology screen and modern cosmic background
The EU is proposing some new regulations on pharmacovigilance • Source: Shutterstock

The European Commission’s proposed reforms of the EU medicines legislation envisage a few noteworthy changes to the pharmacovigilance regulatory framework, including a relaxation of some requirements relating to generics and biosimilars and a firmer legal footing for safety data reporting on the off-label use of medicines.

Under the proposals, released on 26 April, marketing authorization holders (MAHs) would broadly retain the same pharmacovigilance obligations as at...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

Plans For EU Biotech Act Shift Up A Gear

 

Companies have until early November to respond to a public consultation from the European Commission on its planned Biotech Act, which it hopes will help unleash the potential of small and midsize enterprises in the bloc.

EU CHMP Opinions And MAA Updates

 

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

Vaccine Developers To Benefit From CEPI’s ‘World First’ Adjuvant ‘Matchmaking’ Service

 

Selected vaccine developers will soon be able to use a new adjuvant “matchmaking” initiative that could help create more “effective, potent” vaccines against epidemic and pandemic threats, the Coalition for Epidemic Preparedness Innovations has said.

EMA Tackles Guidance Void As Proposals For External Controls Grow

 

The European Medicines Agency is working on defining when and how external controls can be accepted in clinical research. Among other things, it is looking at the planning, design, conduct, analysis and reporting of studies for which external controls are used.

More from Geography

Japan Gives Global-First Recommendations To Taisho’s Vornorexant, Santen’s Sepetaprost

 
• By 

Japan gives world-first approval recommendations to two domestically originated drugs, for insomnia and glaucoma/ocular hypertension.

August Brings Fresh Faces And Tough Calls To US FDA User Fee Calendar

 

The FDA could act on 17 applications, including 10 novel agents, during August. Only one would be a second-cycle review.

Court Allows MSN Marketing Of Entresto Generic, But More Legal Issues Pending

 
• By 

Novartis failed to stop MSN from launching a generic Entresto and saw an earlier temporary ban lifted, potentially opening the market to competition before a final decision on a US patent dispute.